Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 10, 2011, Pages 2280-2287

  Davidsson, Sabina ^a   Fiorentino, Michelangelo ^b,c   Andrén, Ove ^a   Fang, ^d,g   Mucci, Lorelei A ^d,e   Varenhorst, Eberhard ^f   Fall, Katja ^e,g   Rider, Jennifer R ^a,c  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^g KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; ATROPHY; CANCER RISK; CANCER STAGING; CHRONIC INFLAMMATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; GLEASON SCORE; HUMAN; HUMAN TISSUE; INFLAMMATION; LETHALITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; SWEDEN; TRANSURETHRAL RESECTION;

ATROPHY; CASE-CONTROL STUDIES; COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MALE; NEOPLASM GRADING; PROGNOSIS; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RISK FACTORS; SWEDEN;

EID: 80053544187     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0373     Document Type: Article

References (37)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7. (Pubitemid 36019639)
2. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45. (Pubitemid 32173595)
3. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
4. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-81. (Pubitemid 36886244)
5. Blumenfeld W, Tucci S, Narayan P. Incidental lymphocytic prostatitis. Selective involvement with nonmalignant glands. Am J Surg Pathol 1992;16:975-81.
6. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999;155:1985-92.
7. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, Van Poppel H, et al. EAU guidelines on prostate cancer. Eur Urol 2005;48:546-51. (Pubitemid 41278578)
8. Ruska KM, Sauvageot J, Epstein JI. Histology and cellular kinetics of prostatic atrophy. Am J Surg Pathol 1998;22:1073-7. (Pubitemid 28411064)
9. McNeal JE. Prostate cancer volume. Am J Surg Pathol 1997;21:1392-3.
10. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005;26:1170-81. (Pubitemid 41417894)
11. Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol 2004;171:S36-40. (Pubitemid 38090420)
12. Putzi MJ, De Marzo AM. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 2000;56:828-32.
13. Wang W, Bergh A, Damber JE. Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate. Prostate 2009;69:1378-86.
14. De Marzo AM, Putzi MJ, Nelson WG. New concepts in the pathology of prostatic epithelial carcinogenesis. Urology 2001;57:103-14.
15. Shah R, Mucci NR, Amin A, Macoska JA, Rubin MA. Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander? Am J Pathol 2001;158:1767-73. (Pubitemid 32422941)
16. Anton RC, Kattan MW, Chakraborty S, Wheeler TM. Postatrophic hyperplasia of the prostate: lack of association with prostate cancer. Am J Surg Pathol 1999;23:932-6. (Pubitemid 29360111)
17. Macoska JA, Trybus TM, Wojno KJ. 8p22 loss concurrent with 8c gain is associated with poor outcome in prostate cancer. Urology 2000;55:776-82.
18. Andren O, Fall K, Franzen L, Andersson SO, Johansson JE, Rubin MA. How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol 2006;175:1337-40.
19. Aus G, Robinson D, Rosell J, Sandblom G, Varenhorst E. Survival in prostate carcinoma-outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden. Cancer 2005;103:943-51. (Pubitemid 40270070)
20. Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-9. (Pubitemid 38725420)
21. De Marzo AM, Platz EA, Epstein JI, Ali T, Billis A, Chan TY, et al. A working group classification of focal prostate atrophy lesions. Am J Surg Pathol 2006;30:1281-91. (Pubitemid 44454708)
22. Gerstenbluth RE, Seftel AD, MacLennan GT, Rao RN, Corty EW, Ferguson K, et al. Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. J Urol 2002;167:2267-70. (Pubitemid 34309717)
23. Kaplan SA. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. J Urol 2005;173:161.
24. Asimakopoulos AD, Miano R, Mauriello A, Costantini S, Pasqualetti P, Liberati E, et al. Significance of focal proliferative atrophy lesions in prostate biopsy cores that test negative for prostate carcinoma. Urol Oncol 2010. [Epub ahead of print]
25. Alcover J, Filella X, Luque P, Molina R, Izquierdo L, Auge JM, et al. Prognostic value of IL-6 in localized prostatic cancer. Anticancer Res 2010;30:4369-72.
26. Lin HC, Liu CC, Kang WY, Yu CC, Wu TT, Wang JS, et al. Influence of cytokine gene polymorphisms on prostate-specific antigen recurrence in prostate cancer after radical prostatectomy. Urol Int 2009;83:463-70.
27. Stark JR, Judson G, Alderete JF, Mundodi V, Kucknoor AS, Giovannucci EL, et al. Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study. J Natl Cancer Inst 2009;101:1406-11.
28. Sutcliffe S, Giovannucci E, Gaydos CA, Viscidi RP, Jenkins FJ, Zenilman JM, et al. Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 2007;16:1573-80. (Pubitemid 47294821)
29. Cohen RJ, Shannon BA, McNeal JE, Shannon T, Garrett KL. Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution? J Urol 2005;173:1969-74. (Pubitemid 40675222)
30. Fassi Fehri L, Mak TN, Laube B, Brinkmann V, Ogilvie LA, Mollenkopf H, et al. Prevalence of Propionibacterium acnes in diseased prostates and its inflammatory and transforming activity on prostate epithelial cells. Int J Med Microbiol 2011;301:69-78.
31. Billis A, Magna LA. Inflammatory atrophy of the prostate. Prevalence and significance. Arch Pathol Lab Med 2003;127:840-4. (Pubitemid 36792311)
32. De Marzo AM, Nelson WG, Meeker AK, Coffey DS. Stemcell features of benign and malignant prostate epithelial cells. J Urol 1998;160:2381-92.
33. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, deKernion JB, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998;159:941-5. (Pubitemid 28106561)
34. Qian J, Bostwick DG, Takahashi S, Borell TJ, Herath JF, Lieber MM, et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 1995;55:5408-14.
35. Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstralh EJ, et al. Clinical significance of alterations of chromosome 8 in highgrade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst 1999;91:1574-80. (Pubitemid 29457963)
36. De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI, et al. Pathological and molecular mech anisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 2004;91:459-77.
37. Rider JR, Mucci LA, Fall K, Andrén O, Andersson S-O, Stampfer MJ, et al. The epidemiological and pathological implications of focal atrophy lesions: data from cohorts from the United States and Sweden. Italian Society of Uro-Oncology Annual Meeting, June 25, 2010, Rome, Italy.